You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Investigational Drug Information for Bufotenin


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Bufotenin?

Bufotenin is an investigational drug.

There have been 5 clinical trials for Bufotenin. The most recent clinical trial was a Phase 1 trial, which was initiated on March 7th 2023.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Disease. The leading clinical trial sponsors are GH Research Ireland Limited and [disabled in preview].

There are eighty-six US patents protecting this investigational drug and four hundred and ninety-six international patents.

Recent Clinical Trials for Bufotenin
TitleSponsorPhase
Phase 2 Clinical Trial of GH001 in Bipolar II DisorderGH Research Ireland LimitedPhase 2
A Trial of GH001 in Patients With Treatment-resistant DepressionGH Research Ireland LimitedPhase 2
Phase 2 Clinical Trial of GH001 in Postpartum DepressionGH Research Ireland LimitedPhase 2

See all Bufotenin clinical trials

Clinical Trial Summary for Bufotenin

Top disease conditions for Bufotenin
Top clinical trial sponsors for Bufotenin

See all Bufotenin clinical trials

US Patents for Bufotenin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bufotenin ⤷  Subscribe Pharmaceutical compositions resistant to abuse EGALET LTD. (London, GB) ⤷  Subscribe
Bufotenin ⤷  Subscribe Abuse-deterrent controlled release formulations Patheon Softgels Inc. (High Point, NC) ⤷  Subscribe
Bufotenin ⤷  Subscribe Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features Pisgah Laboratories, Inc. (Pisgah Forest, NC) ⤷  Subscribe
Bufotenin ⤷  Subscribe Enteric soft capsule compositions Patheon Softgels Inc. (High Point, NC) ⤷  Subscribe
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bufotenin

Drugname Country Document Number Estimated Expiration Related US Patent
Bufotenin Australia AU2010211376 2029-02-06 ⤷  Subscribe
Bufotenin Australia AU2013257533 2029-02-06 ⤷  Subscribe
Bufotenin Canada CA2751627 2029-02-06 ⤷  Subscribe
Bufotenin Denmark DK2393487 2029-02-06 ⤷  Subscribe
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.